Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
palivizumab + motavizumab
- Development stage
- Unknown
- Lead developer
- MedImmune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Palivizumab and motavizumab are humanized monoclonal antibodies (mAbs) developed by MedImmune (AstraZeneca) for the prevention of respiratory syncytial virus (RSV) infection in high-risk infants. Both antibodies target the highly conserved antigenic site A of the RSV fusion (F) protein, neutralizing the virus by preventing virus-to-cell and cell-to-cell fusion. Palivizumab (Synagis) is the first-generation FDA-approved mAb, while motavizumab (MEDI-524) is a second-generation, affinity-optimized version engineered with 13 amino acid substitutions to enhance binding and potency. Clinical trials, such as NCT00316264, have evaluated the safety and immunogenicity of these antibodies when administered sequentially during the same RSV season.
- Brand names
- Synagis
- Other names
- palivizumabmotavizumab
02
Targets
C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)RSV F (Respiratory syncytial virus fusion protein)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on palivizumab + motavizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on palivizumab + motavizumab.